Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?

Basit Öğe Kaydı
dc.authoridCortuk, Mustafa/0000-0002-6923-736X
dc.contributor.authorTanriverdi, Elif
dc.contributor.authorIliaz, Sinem
dc.contributor.authorCortuk, Mustafa
dc.contributor.authorTuran, Demet
dc.contributor.authorChousein, Efsun Gonca Ugur
dc.contributor.authorGul, Sule
dc.contributor.authorOzgul, Mehmet Akif
dc.date.accessioned2024-09-29T16:09:45Z
dc.date.available2024-09-29T16:09:45Z
dc.date.issued2020
dc.departmentKarabük Üniversitesien_US
dc.descriptionInternational Congress of the European-Respiratory-Society (ERS) -- SEP 09-13, 2017 -- Milan, ITALYen_US
dc.description.abstractOBJECTIVES: Sarcoidosis is a chronic systemic inflammatory disease that affects multiple organ systems. The role of biomarkers in the diagnosis and prognosis of sarcoidosis is increasing. Interest in the role of adipose tissue-mediated inflammation in the pathogenesis of inflammatory diseases has increased in recent years. Visfatin is a proinflammatory adipocytokine that has been studied for several inflammatory diseases such as diabetes mellitus, obesity, and metabolic syndrome. We aimed to assess serum visfatin levels in sarcoidosis and its relationship with other markers of inflammation such as C-reactive protein (CRP), angiotensin-converting enzyme (ACE) and erythrocyte sedimentation rate (ESR). MATERIALS AND METHODS: We enrolled 59 patients with sarcoidosis and 21 healthy controls and measured plasma levels of visfatin, along with serum CRP, ESR, and ACE using ELISA (enzyme-linked immunosorbent assay) kits (Blue Gene Biotech, Shanghai, China). RESULTS: Visfatin levels did not differ significantly between the patients and control subjects (29.9 +/- 15.8 ng/mL for patients and 23.93 +/- 16.73 ng/mL for controls, p=0.15), and there was no correlation between visfatin and serum CRP, ACE, or ESR in patients with sarcoidosis. CONCLUSION: Visfatin is recently being discussed as a biomarker for inflammatory diseases in several studies, and results are controversial. In our study, no differences were found in the serum levels of visfatin between patients with sarcoidosis and the control group.en_US
dc.description.sponsorshipEuropean Respiratory Socen_US
dc.identifier.doi10.5152/TurkThoracJ.2019.180112
dc.identifier.endpage149en_US
dc.identifier.issn2149-2530
dc.identifier.issue3en_US
dc.identifier.pmid32584229en_US
dc.identifier.scopus2-s2.0-85086941584en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage145en_US
dc.identifier.trdizinid370725en_US
dc.identifier.urihttps://doi.org/10.5152/TurkThoracJ.2019.180112
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/370725
dc.identifier.urihttps://hdl.handle.net/20.500.14619/7737
dc.identifier.volume21en_US
dc.identifier.wosWOS:000540904400002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Thoracic Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiomarkersen_US
dc.subjectinflammationen_US
dc.subjectsarcoidosisen_US
dc.subjectvisfatinen_US
dc.titleEvaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu